These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38187068)

  • 1. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.
    Parker CS; Zhou L; Prabhu VV; Lee S; Miner TJ; Ross EA; El-Deiry WS
    Am J Cancer Res; 2023; 13(12):6290-6312. PubMed ID: 38187068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
    Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.
    Kline CL; Van den Heuvel AP; Allen JE; Prabhu VV; Dicker DT; El-Deiry WS
    Sci Signal; 2016 Feb; 9(415):ra18. PubMed ID: 26884600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
    Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic.
    Ralff MD; Jhaveri A; Ray JE; Zhou L; Lev A; Campbell KS; Dicker DT; Ross EA; El-Deiry WS
    Oncotarget; 2020 Oct; 11(42):3753-3769. PubMed ID: 33144917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis.
    Di Cristofano FR; Fong MW; Huntington KE; Carneiro BA; Zhou L; El-Deiry WS
    Am J Cancer Res; 2023; 13(1):307-325. PubMed ID: 36777502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK; Allen JE; Dicker DT; El-Deiry WS
    Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.
    Zhang Y; Tapinos N; Lulla R; El-Deiry WS
    Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
    Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
    Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
    Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
    Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
    Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
    Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
    Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ONC201: a new treatment option being tested clinically for recurrent glioblastoma.
    Ralff MD; Lulla AR; Wagner J; El-Deiry WS
    Transl Cancer Res; 2017 Oct; 6(Suppl 7):S1239-S1243. PubMed ID: 30175049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
    Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.
    Ni X; Zhang X; Hu CH; Langridge T; Tarapore RS; Allen JE; Oster W; Duvic M
    Oncotarget; 2017 Sep; 8(37):61761-61776. PubMed ID: 28977902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.
    Feng Y; Zhou J; Li Z; Jiang Y; Zhou Y
    PLoS One; 2016; 11(9):e0162133. PubMed ID: 27626799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.